Business
CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®
-Update provided for both Part A (single dose with optional re-dosing) and Part B (consolidation dosing) of the Phase 1 CARBON™ clinical trial- -Part A data
About this update from Crispr Therapeutics Ag
[{"type":"text","content":"-Update provided for both Part A (single dose with optional re-dosing) and Part B (consolidation dosing) of the Phase 1 CARBON™ clinical trial- -Part A data presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition confirm that CTX110® can lead to long-term durable complete remissions (CRs) for heavily pre-treated Large B-cell Lymphoma (LBCL) patients; three patients remain in CR beyond two years- -Emerging data from Part B demonstrate the benefits of consolidation dosing with a positively differentiated safety profile consistent with Part A- -Based on discussions with regulatory agencies, the Company has initiated a Phase 2 single-arm potentially registrational trial with drug product manufactured using a commercial-ready process and specifications- ZUG, Switzerland and BOSTON, Dec. 12, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today provided an update for both Part A and Part B of the Company’s ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110®, its wholly-owned allogeneic CAR T cell therapy targeting CD19+ B-cell malignancies. Part A data, presented at ASH, showed the potential for CTX110 to achieve long-term durable complete remissions (CRs) with a positively differentiated safety profile in heavily pre-treated patients, and emerging data from Part B showed an encouraging efficacy profile with several patients in ongoing CR beyond six months. “We are excited by these results in our CARBON trial, which demonstrate the potential of a single course of allogeneic CAR T treatment to produce long-lasting complete remissions in heavily pre-treated patients with LBCL,” said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. “Furthermore, we are encouraged by the emerging data using consolidation dosing, which has the potential to further improve the efficacy profile while maintaining a positively differentiated safety profile. Based on these results, we have initiated a potentially registrational Phase 2 trial of CTX110 incorporating consolidation dosing with the hope of bringing this important therapy to patients in the near term.” CARBON Trial OverviewThe Phase 1 CARBON trial is an open-label, multicenter clinical trial evaluating t...